News | February 18, 2023
Lupin receives EIR from USFDA for injectable facility in Nagpur
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
The Ministry of Ayush endeavour is to get entry level NABH certification for 12,500 Ayush Wellness Centers by the end of 2023
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
Subscribe To Our Newsletter & Stay Updated
